At A Glance
1
Helix BioPharma Corp.
2
No significant events in the past 90 days.
—
Market Cap
—
Revenue
—
Net Income
Employees7
Fundamentals
How The Business Makes Money
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Industry Biotechnology
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIKUNKNOWN_HBPCF
ISINCA4229102088
Address401 Bay Street, Toronto, ON, M5H 2Y4, CA
SEC EDGAR